A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. Study investigators aim to enroll more than 500 people from clinical research sites nationwide. Interested volunteers can visit the ACTG website (clinical trial A5418) for more information. The NIAID-funded Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) is leading the study, which may later expand to international sites. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at NIH is supporting several sites, including through the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT).

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines. NIAID is sponsoring the study, called HVTN 302, and the NIAID-funded HIV Vaccine Trials Network (HVTN), based at Fred Hutchinson Cancer Research Center in Seattle, is conducting the trial.

The Clinical Studies Support Team (CSST) develops and fosters overseas relationships through continuous support of research studies and clinical trials involving pathogens of high consequence. When deployed, the team provides in-person training and assistance with assays, equipment, and project management.

The drug screening team tests and characterizes novel compounds, drugs, and antibodies against numerous viruses in multiple cell lines under a variety of conditions. Compounds are evaluated in cell-based assays for inhibition of viral replication and reduction of virus yields, plaques, or cytopathic effect. In addition, recombinant reporter gene viruses are available as tools for antiviral screening.

PathogenAR is an Augmented Reality application from the National Institute for Allergy and Infectious Diseases (NIAID). Explore interactive stories about pathogens and pathogenic disease using touch gestures or a Merge Cube Device.

The Process Development and Analytical Support Contract (PAS) supports two key critical components: process development and analytical characterization activities. 

This contract is with the International AIDS Vaccine Initiative (IAVI).

The Preclinical Development Support Master Contract (PDSMC) supports all phases of preclinical development, including process and product development, GMP manufacturing and clinical lot production, analytical and formulation, preclinical enabling studies and associated tasks leading to the filing of investigational new drug (IND) applications.

This contract is with Advanced Bioscience Laboratories (ABL).

The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who integrate experimental biology, computational tools and modeling across temporal and spatial scales to improve our understanding of infectious diseases. Through collaborative efforts, scientists test and validate hypotheses that drive innovation and discovery. The Consortium seeks to develop strategies that predict and alleviate disease severity and ultimately provide solutions to the world's most important health challenges.

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

The original MACS collected and stored a variety of biological specimens. Inventory may be housed at the national level or a subset at the local level. The now combined MACS-WIHS Combined Cohort Study (MWCCS) Data Analysis and Coordinating Center (DACC) coordinates and facilitates completion of specimen requests.